{"name":"Guangzhou Zhiyi Biotechnology Co., Ltd.","slug":"guangzhou-zhiyi-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Live SK08 powder","genericName":"Live SK08 powder","slug":"live-sk08-powder","indication":"Indication under investigation in Phase 3 (specific indication not publicly disclosed)","status":"phase_3"}]}],"pipeline":[{"name":"Live SK08 powder","genericName":"Live SK08 powder","slug":"live-sk08-powder","phase":"phase_3","mechanism":"Live SK08 powder is a live attenuated bacterial vaccine designed to stimulate immune responses against specific pathogens or disease targets.","indications":["Indication under investigation in Phase 3 (specific indication not publicly disclosed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQdTBXSFM0UUEta0d0UXM2ZlFKUGsxMzlBYUxGRjhQVkM2NEMwcXlNRXNlLThLcG41UUczN3dWWVZjalJmZnluNE1BT1dkZXliMC1yX1pVQ2stNWxuMGRlQjFuT3VScGVGZTAwdWRsbWhyNjZPc1JKc0pEcW1jd3VHRjlxS2Vid1JiZTF3R00tVDBURnJIQzBSLQ?oc=5","date":"2025-12-26","type":"pipeline","source":"MarketsandMarkets","summary":"Human Microbiome Drugs Market Report 2026-2031, By Type, Disease, and Geo - MarketsandMarkets","headline":"Human Microbiome Drugs Market Report 2026-2031, By Type, Disease, and Geo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPbWpvU292dU9tbzNNRU84QVhzdmlybnNwbGRxb1BuZm1jWjlNQlJXUFZpT1BGTU93eTJfNUhZNFBEZGtHX3JhSFZ2aVFtbGNvel9DRTZUYnl4SVZjTnlXMksyTHU4enpIb3ZmSmJyQ1dzbTFadjRWV1ZEQ010d3E3RkR0SmdlUmtBWU9MX1hMTU1lME9HTVZJTHE4ejU4cVVwcVJvM25TUjZKRmFKV0IzRGhQbUZoRjJabjZyRzg1Tnk0dHFVTVN6TkNBSEFOY0dQdE13Tm5iZHVCdkVEXzBVVEdZUEoyUmNKbk84RS0zYmVXUk45MEt2dWE3VlAwbFE?oc=5","date":"2022-07-07","type":"pipeline","source":"prnewswire.com","summary":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines - prnewswire.com","headline":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQNmhKVkVmOEVienRVN1dPaFEzT0wzRDNrd0hPX19KWlpkZFRaSEFLcVE4bWQxeVFQSkFFTllzRjhoNGJ1UV9nYkNaeFRlZ3N0ejZhcllyTVpUejdVbmt1SV9jdUFUdko1QXJYVy16dlhCSFlfSGNlWng1ZU9zUGJENDFnR2FFRnY2WjQ4Tk9JNA?oc=5","date":"2016-03-31","type":"pipeline","source":"MarketsandMarkets","summary":"Human Microbiome Market Report 2026-2031, By Product, Disease, and Geo - MarketsandMarkets","headline":"Human Microbiome Market Report 2026-2031, By Product, Disease, and Geo","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}